AZ
AZTA.US Azenta Inc
- Market cap
- USD 1.91B
- P/E
- -
- P/B
- 1.36x
- ROE
- -12.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is AZTA.US undervalued?
Graham numberThe Graham number of Azenta Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Azenta Inc fundamental analysis
No fundamental analysis for Azenta Inc yet.
Azenta Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Azenta Inc
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables…
Full company profileAzenta Inc financial statements
Azenta Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 527M | 632M | 781M | 389M | 514M | 555M | 665M | 573M | 594M | 622M |
| Gross Profit | 186M | 227M | 292M | 145M | 215M | 231M | 233M | 255M | 270M | 275M |
| Operating Income | 18.2M | 34.4M | 55.1M | -27.5M | 3.60M | -24.0M | -82.2M | -30.0M | -11.3M | -175M |
| EBITDA | 43.1M | 67.4M | 86.1M | 28.1M | 9.94M | 48.4M | 55.2M | 71.6M | 54.1M | -151M |
| Net Income | 62.6M | 117M | 28.8M | 64.9M | 111M | -429M | -14.3M | -165M | -55.8M | -167M |
| EPS | 0.89 | 1.64 | 0.40 | 0.88 | 1.49 | -5.73 | -0.22 | -3.10 | -1.21 | -3.70 |
| Balance Sheet | ||||||||||
| Total Assets | 767M | 1.10B | 1.52B | 1.56B | 1.82B | 3.72B | 2.89B | 2.10B | 2.06B | 1.71B |
| Total Liabilities | 159M | 378M | 378M | 346M | 494M | 353M | 351M | 331M | 331M | 311M |
| Shareholders' Equity | 608M | 718M | 1.14B | 1.21B | 1.33B | 3.36B | 2.53B | 1.77B | 1.73B | 1.40B |
| Cash & Short-term Investments | 102M | 244M | 336M | 296M | 228M | 1.57B | 1.02B | 462M | 341M | 333M |
| Total Debt | - | 196M | 51.1M | 82.3M | 94.8M | 49.2M | 60.4M | 70.7M | 111M | 51.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 96.2M | 74.0M | 90.9M | 37.9M | 150M | -466M | 5.83M | 49.7M | 72.2M | 57.5M |
| Capital Expenditure | 12.9M | 12.8M | 23.9M | 39.9M | 52.8M | 77.4M | 39.4M | 37.4M | 33.9M | 30.1M |
| Free Cash Flow | 83.3M | 61.2M | 67.0M | -2.06M | 97.1M | -543M | -33.6M | 12.4M | 38.3M | 27.4M |
| Ratios | ||||||||||
| ROE | 10.3% | 16.2% | 2.5% | 5.3% | 8.4% | -12.8% | -0.6% | -9.3% | -3.2% | -12.0% |
| ROA | 8.2% | 10.6% | 1.9% | 4.2% | 6.1% | -11.5% | -0.5% | -7.9% | -2.7% | -9.8% |
| Net Profit Margin | 11.9% | 18.5% | 3.7% | 16.7% | 21.6% | -77.2% | -2.1% | -28.8% | -9.4% | -26.9% |
| Debt to Equity | - | 0.27x | 0.04x | 0.07x | 0.07x | 0.01x | 0.02x | 0.04x | 0.06x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Azenta Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 2, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 7.49M | 0.10 | - |
| 2021 | USD 29.7M | 0.40 | 26.8% |
| 2020 | USD 29.5M | 0.40 | 45.5% |
| 2019 | USD 28.9M | 0.40 | 100.3% |
| 2018 | USD 28.3M | 0.40 | 24.3% |
| 2017 | USD 27.9M | 0.40 | 44.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Azenta Inc
- Insiders 1.95%
- Institutions 98.05%
- Public & others 0.00%
- Shares outstanding 41.8M
- Free float 36.8M
Top funds holding AZTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.38M | 5.42% | +0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.25M | 2.86% | -5.24% | Sep 2026 |
| iShares Russell 2000 ETF | 1.07M | 2.44% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 888K | 2.03% | -6.93% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 577K | 1.32% | -4.77% | Sep 2026 |
| Columbia Small Cap Value Discv A | 493K | 1.13% | +0.74% | Sep 2026 |
| Fidelity Small Cap Index | 461K | 1.05% | +0.30% | Aug 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 450K | 1.03% | +210.96% | Jun 2026 |
| iShares Russell 2000 Value ETF | 398K | 0.91% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap Value I | 391K | 0.89% | +2.84% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 366K | 0.83% | 0.00% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 359K | 0.82% | -0.05% | Oct 2026 |
| Tarkio | 356K | 0.81% | -25.91% | Aug 2026 |
| Allspring Special Small Cap Value A | 354K | 0.81% | -10.52% | Sep 2026 |
| Avantis US Small Cap Value ETF | 351K | 0.80% | 0.00% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 311K | 0.71% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 305K | 0.70% | -6.89% | Sep 2026 |
| Royce Small-Cap Opportunity Invmt | 290K | 0.66% | +6.59% | Sep 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 265K | 0.60% | -10.40% | Sep 2026 |
| Neuberger Intrinsic Value I | 264K | 0.60% | 0.00% | Sep 2026 |
Top institutions holding AZTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.53M | 17.19% | +11.96% | Jun 2026 |
| Politan Capital Management LP | 4.62M | 10.55% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.49M | 5.69% | +1.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.87M | 4.27% | +2.29% | Jun 2026 |
| State Street Corp | 1.86M | 4.25% | +5.53% | Jun 2026 |
| Massachusetts Financial Services Company | 1.42M | 3.25% | -20.38% | Jun 2026 |
| D. E. Shaw & Co LP | 1.34M | 3.06% | +97.48% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.33M | 3.04% | +53.67% | Jun 2026 |
| Front Street Capital Management Inc | 1.30M | 2.97% | +46.39% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.20M | 2.74% | -2.74% | Sep 2026 |
| Allspring Global Investments Holdings, LLC | 1.19M | 2.72% | -26.14% | Jun 2026 |
| Neuberger Berman Group LLC | 1.13M | 2.58% | +25.26% | Jun 2026 |
| Geode Capital Management, LLC | 1.10M | 2.51% | +9.04% | Jun 2026 |
| American Capital Management Inc | 1.06M | 2.42% | -18.10% | Jun 2026 |
| GW&K Investment Management, LLC | 988K | 2.26% | +1.56% | Jun 2026 |
| Royce & Associates, LP | 891K | 2.03% | +70.34% | Jun 2026 |
| Snyder Capital Management LP | 873K | 1.99% | +2,528.62% | Jun 2026 |
| Victory Capital Management Inc. | 854K | 1.95% | +2.07% | Jun 2026 |
| Ameriprise Financial Inc | 768K | 1.75% | +196.26% | Jun 2026 |
| Bank of America Corp | 668K | 1.53% | +42.81% | Jun 2026 |
Azenta Inc company profile
- Company name
- Azenta Inc
- Ticker
- AZTA.US
- Exchange
- USA Stocks
- Listed since
- Feb 2, 1995
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 2,900
- Fiscal year end
- September
- Address
- 200 Summit Drive, Burlington, MA, United States, 01803
- Phone
- 888 229 3682
- Website
- azenta.com
About Azenta Inc
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Azenta Inc management
10- Dr. Martin D. Madaus D.V.M., Ph.D.Interim President, CEO & Director · born 1960
- Mr. Lawrence Y. LinExecutive VP & CFO · born 1977
- Mr. Ephraim StarrSenior VP, General Counsel & Corporate Secretary · born 1972
- Ms. Olga PirogovaSenior VP & Chief HR Officer · born 1974
- Dr. Ginger Zhou Ph.D.Advisor · born 1977
- Mr. Erik J. BelloVice President, Chief Accounting Officer & Principal Accounting Officer
- Mr. Michael PauloVP, Chief Information & Digital Officer
- Ms. Yvonne PerronVice President of Financial Planning & Analysis and Investor Relations
- Mr. William E. Martin IIISenior Vice President & President of Multiomics · born 1975
- Dr. Andrea O'Hara Ph.D.Strategic Technical Specialist of Azenta Life Sciences